Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection

被引：63
作者：
Hou, Yi-Chou [1 ,2 ]
Zheng, Cai-Mei [3 ,4 ,5 ]
Yen, Tzung-Hai [6 ,7 ]
Lu, Kuo-Cheng [8 ]
机构：
[1] Fu Jen Catholic Univ, Cardinal Tien Hosp, Sch Med, Dept Med,Div Nephrol, New Taipei 234, Taiwan
[2] Taipei Med Univ, Coll Med, Sch Med, Grad Inst Clin Med, Taipei 110, Taiwan
[3] Taipei Med Univ, Dept Internal Med, Div Nephrol, Shuang Ho Hosp, New Taipei 235, Taiwan
[4] Taipei Med Univ, Coll Med, Sch Med, Div Nephrol,Dept Internal Med, Taipei 110, Taiwan
[5] Taipei Med Univ, Res Ctr Urol & Kidney, Taipei 110, Taiwan
[6] Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, Taipei 105, Taiwan
[7] Chang Gung Univ, Coll Med, Dept Med, Taoyuan 333, Taiwan
[8] Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med, Div Nephrol, New Taipei 231, Taiwan
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 21期
关键词：
cardiovascular disease; chronic kidney disease; SGLT2; diabetes mellitus; COTRANSPORTER; 2; INHIBITOR; SYMPATHETIC-NERVOUS-SYSTEM; GLOMERULAR-FILTRATION RATE; GLUCOSE-TRANSPORTER SGLT2; NA+/H+ EXCHANGER NHE3; BLOOD-PRESSURE; DIABETIC-NEPHROPATHY; URIC-ACID; KIDNEY-DISEASE; URINARY-EXCRETION;
D O I：
10.3390/ijms21217833
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre- and post- glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.
引用
收藏
页码：1 / 25
页数：25
相关论文
共 165 条
  • [1] Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
    Ansary, Tuba M.
    Nakano, Daisuke
    Nishiyama, Akira
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03)
  • [2] Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats
    Ansary, Tuba M.
    Fujisawa, Yoshihide
    Rahman, Asadur
    Nakano, Daisuke
    Hitomi, Hirofumi
    Kobara, Hideki
    Masaki, Tsutomu
    Titze, Jens M.
    Kitada, Kento
    Nishiyama, Akira
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [3] Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies
    Anzai, Naohiko
    Jutabha, Promsuk
    Amonpatumrat-Takahashi, Sirirat
    Sakurai, Hiroyuki
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (01) : 89 - 95
  • [4] Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
    Baker, William L.
    Smyth, Lindsay R.
    Riche, Daniel M.
    Bourret, Emily M.
    Chamberlin, Kevin W.
    White, William B.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (04) : 262 - 275
  • [5] Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance
    Bidani, Anil K.
    Picken, Maria
    Hacioglu, Rifat
    Williamson, Geoffrey
    Griffin, Karen A.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 292 (02) : F647 - F654
  • [6] Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
    Bilezikian, John P.
    Watts, Nelson B.
    Usiskin, Keith
    Polidori, David
    Fung, Albert
    Sullivan, Daniel
    Rosenthal, Norm
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (01) : 43 - 50
  • [7] Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
    Bjornstad, Petter
    Nelson, Robert G.
    Pavkov, Meda E.
    [J]. KIDNEY INTERNATIONAL, 2020, 97 (01) : 31 - 33
  • [8] Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
    Bonner, Caroline
    Kerr-Conte, Julie
    Gmyr, Valery
    Queniat, Gurvan
    Moerman, Ericka
    Thevenet, Julien
    Beaucamps, Cedric
    Delalleau, Nathalie
    Popescu, Iuliana
    Malaisse, Willy J.
    Sener, Abdullah
    Deprez, Benoit
    Abderrahmani, Amar
    Staels, Bart
    Pattou, Francois
    [J]. NATURE MEDICINE, 2015, 21 (05) : 512 - U139
  • [9] Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
    Bonnet, F.
    Scheen, A. J.
    [J]. DIABETES & METABOLISM, 2018, 44 (06) : 457 - 464
  • [10] Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease
    Borghi, Claudio
    Agabiti-Rosei, Enrico
    Johnson, Richard J.
    Kielstein, Jan T.
    Lurbe, Empar
    Mancia, Giuseppe
    Redon, Josep
    Stack, Austin G.
    Tsioufis, Konstantinos P.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 80 : 1 - 11
12345678910